Shukra Pharmaceuticals Ltd

Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026. The stock’s recent price action and technical indicators suggest increasing bearish pressure, with the share price retreating 3.42% on 10 June 2026 to close at ₹30.78, down from the previous close of ₹31.87.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical parameters, reflecting a complex interplay of bullish and bearish signals. Despite a modest daily price increase of 1.30%, the stock’s technical indicators reveal a nuanced momentum change, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026.

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market standing.

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 June 2026, providing investors with an up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 30 April 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 14 May 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd. reported a challenging fourth quarter for FY26, with net profit swinging to a loss of ₹1.72 crores from a profit of ₹5.39 crores in the same period last year, marking a sharp 154.43% year-on-year decline. The micro-cap pharmaceutical company, with a market capitalisation of ₹1,469 crores, saw its stock decline 4.99% to ₹33.54 following the results announcement, as investors reacted to the dramatic quarterly reversal despite strong half-yearly performance.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its financial trend, moving from an outstanding to a positive performance rating in the latest quarter ending March 2026. Despite strong half-yearly sales and profit after tax (PAT) figures, the company’s most recent quarterly results reveal significant declines in revenue and profitability compared to its previous four-quarter averages, prompting a downgrade in its Mojo Grade from Hold to Sell.

Shukra Pharmaceuticals Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently experienced a shift in its technical momentum, moving from a mildly bearish to a bearish trend. Despite a modest day change of 0.03%, the stock’s technical indicators reveal a complex picture with mixed signals across weekly and monthly timeframes, prompting a downgrade in its Mojo Grade from Hold to Sell as of 30 April 2026.

Shukra Pharmaceuticals Ltd is rated Sell by MarketsMOJO, with this rating last updated on 30 Apr 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 03 May 2026, providing investors with the most up-to-date perspective on the company’s fundamentals, valuation, financial trends, and technical outlook.

Shukra Pharmaceuticals Ltd has recently formed a Death Cross, a significant technical indicator where the 50-day moving average (DMA) crosses below the 200-DMA. This development signals a potential shift towards a bearish trend, reflecting a deterioration in the stock’s short- to medium-term momentum and raising concerns about its near-term price trajectory.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent upgrade in its Mojo Grade from Sell to Hold, the stock’s technical indicators present a complex picture, with bearish signals dominating weekly charts while monthly indicators offer a more nuanced outlook. This article analyses the latest price momentum, key technical indicators, and the implications for investors navigating the Pharmaceuticals & Biotechnology sector.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, transitioning from a mildly bullish trend to a sideways movement. Despite a recent downgrade in daily price performance, the stock’s monthly indicators suggest underlying strength, presenting a complex picture for investors navigating the Pharmaceuticals & Biotechnology sector.

Shukra Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bullish stance despite a recent 4.58% decline in its share price. The company’s technical indicators present a complex picture, with weekly and monthly signals diverging across key metrics such as MACD, RSI, Bollinger Bands, and moving averages. This nuanced technical landscape warrants a detailed analysis for investors seeking clarity on the stock’s near-term prospects.

Shukra Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 17 Jul 2025. However, the analysis and financial metrics discussed here reflect the company’s current position as of 22 April 2026, providing investors with an up-to-date perspective on the stock’s fundamentals, valuation, financial trends, and technical outlook.